Cooperative Division of Veterinary Sciences, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Sugita Animal Hospital, Saitama, Japan.
Sci Rep. 2023 May 31;13(1):8824. doi: 10.1038/s41598-023-35565-y.
The gut microbiota has been suggested to be involved in the pathogenesis of canine atopic dermatitis (cAD). However, the gut microbiota has not been well characterized in dogs with atopic dermatitis (AD). In addition, the efficacy of fecal microbiota transplantation (FMT) in dogs with AD remains unclear. This research, therefore, aimed to characterize the gut microbiota of dogs with AD and conduct pilot evaluation of the efficacy of a single oral FMT on clinical signs and the gut microbiota of dogs with AD. For these purposes, we used 12 dogs with AD and 20 healthy dogs. The 16S rRNA analysis of the fecal microbiota revealed significant differences between 12 dogs with AD and 20 healthy dogs. Next, a single oral FMT was performed in 12 dogs with AD as a single-arm, open-label clinical trial for 56 days. A single oral FMT significantly decreased Canine Atopic Dermatitis Extent and Severity Index (CADESI)-04 scores from day 0 (median score, 16.5) to day 56 (8) and Pruritus Visual Analog Scale (PVAS) scores from days 0 (median score, 3) to day 56 (1). Furthermore, a single oral FMT changed the composition of the fecal microbiota of dogs with AD at the phylum and genus levels. The number of common amplicon sequence variants in the fecal microbiota between donor dogs and dogs with AD was positively correlated with CADESI-04 and PVAS reduction ratios 56 days after FMT. Our findings suggest that the gut microbiota plays a pivotal role in the pathogenesis of cAD, and that oral FMT could be a new therapeutic approach targeting the gut microbiota in cAD.
肠道微生物群被认为与犬特应性皮炎（cAD）的发病机制有关。然而，特应性皮炎犬的肠道微生物群尚未得到很好的描述。此外，粪便微生物群移植（FMT）在特应性皮炎犬中的疗效仍不清楚。因此，本研究旨在描述特应性皮炎犬的肠道微生物群，并对单次口服 FMT 治疗特应性皮炎犬的临床疗效和肠道微生物群进行初步评估。为此，我们使用了 12 只特应性皮炎犬和 20 只健康犬。粪便微生物群的 16S rRNA 分析显示，12 只特应性皮炎犬和 20 只健康犬之间存在显著差异。接下来，我们对 12 只特应性皮炎犬进行了单次口服 FMT，作为一项为期 56 天的单臂、开放标签临床试验。单次口服 FMT 可显著降低犬特应性皮炎严重程度指数（CADESI-04）评分，从第 0 天（中位数评分 16.5）到第 56 天（8）和瘙痒视觉模拟评分（PVAS）评分，从第 0 天（中位数评分 3）到第 56 天（1）。此外，单次口服 FMT 可改变特应性皮炎犬粪便微生物群的组成，在门和属水平上。供体犬和特应性皮炎犬粪便微生物群中共同扩增子序列变异的数量与 FMT 后 56 天 CADESI-04 和 PVAS 降低率呈正相关。我们的研究结果表明，肠道微生物群在 cAD 的发病机制中起着关键作用，口服 FMT 可能是一种针对 cAD 肠道微生物群的新治疗方法。
